Alphabet's AI drug discovery startup, Isomorphic Labs, a spinoff from Google DeepMind and powered by the AlphaFold technology, is preparing to initiate its first human clinical trials for AI-designed drugs later this year. The company has secured $600 million in funding and formed partnerships with pharmaceutical giants Novartis and Eli Lilly. The trials will focus on AI-designed medicines, including treatments targeting cancer, aiming to accelerate drug development by making it up to ten times faster and reduce costs by approximately 90%. Colin Murdoch, president of Isomorphic Labs, confirmed the company is "getting very close" to starting these trials. Isomorphic Labs' approach leverages AI to predict protein folding and design precise molecular structures, potentially transforming traditional drug discovery processes. The company envisions a future where AI can rapidly generate treatments on demand, which could lead to faster, cheaper, and more accurate drug development. This advancement raises questions about how regulatory frameworks like the FDA will adapt to the accelerated lab-to-patient timelines enabled by AI. Industry observers highlight that this development could redefine pharmaceutical innovation and healthcare delivery.